started · updated
SEMNIM warns of long-term cardiac risks for cancer survivors
The Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM) warns that cancer survivors may require cardiac monitoring for up to 20 years following treatment. Certain oncological therapies can cause cardiotoxicity, a silent damage to the heart that may not manifest until one or two decades after chemotherapy has concluded.
Dr. Francisco Sebastián Palacid, coordinator of the SEMNIM Cardiology Working Group, notes that while damage can appear acutely within the first year, late-onset effects are common, particularly in those treated during childhood. Children and adolescents are identified as the most sensitive group, especially those treated for leukemia or sarcomas, as high doses can affect a developing cardiac muscle.
Other high-risk groups include women with breast cancer treated with a combination of anthracyclines and trastuzumab, as well as lymphoma patients treated with anthracyclines and potentially thoracic radiotherapy. Experts emphasize that medical follow-up must extend well beyond the active treatment phase for these high-risk individuals.
Entities
Francisco Sebastián Palacid · Hospital Clínico Universitario de Valladolid · Sociedad Española de Medicina Nuclear e Imagen Molecular